Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
/ pharmacology
Animals
Benzimidazoles
Biphenyl Compounds
COVID-19
Captopril
/ pharmacology
Humans
Pandemics
Peptidyl-Dipeptidase A
/ metabolism
Rats
Renin-Angiotensin System
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Tetrazoles
ACE2
ADAM17
COVID-19
angiotensin II type 1 receptor blocker
angiotensin-converting enzyme inhibitor
Journal
Clinical science (London, England : 1979)
ISSN: 1470-8736
Titre abrégé: Clin Sci (Lond)
Pays: England
ID NLM: 7905731
Informations de publication
Date de publication:
30 04 2021
30 04 2021
Historique:
received:
16
03
2021
revised:
08
04
2021
accepted:
12
04
2021
entrez:
21
4
2021
pubmed:
22
4
2021
medline:
11
5
2021
Statut:
ppublish
Résumé
Angiotensin-converting enzyme 2 (ACE2) is the leading player of the protective renin-angiotensin system (RAS) pathway but also the entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). RAS inhibitors seemed to interfere with the ACE2 receptor, and their safety was addressed in COVID-19 patients. Pedrosa et al. (Clin. Sci. (Lond.) (2021), 135, 465-481) showed in rats that captopril and candesartan up-regulated ACE2 expression and the protective RAS pathway in lung tissue. In culture of pneumocytes, the captopril/candesartan-induced ACE2 up-regulation was associated with inhibition of ADAM17 activity, counterbalancing increased ACE2 expression, which was associated with reduced SARS-CoV-2 spike protein entry. If confirmed in humans, these results could become the pathophysiological background for justifying RAS inhibitors as cornerstone cardiovascular protectives even during COVID-19 pandemic.
Identifiants
pubmed: 33881142
pii: 228423
doi: 10.1042/CS20210182
pmc: PMC8062870
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Benzimidazoles
0
Biphenyl Compounds
0
Spike Glycoprotein, Coronavirus
0
Tetrazoles
0
spike protein, SARS-CoV-2
0
Captopril
9G64RSX1XD
Peptidyl-Dipeptidase A
EC 3.4.15.1
candesartan
S8Q36MD2XX
Types de publication
Journal Article
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
1009-1014Commentaires et corrections
Type : CommentOn
Informations de copyright
© 2021 The Author(s).
Références
Clin Sci (Lond). 2021 Feb 12;135(3):465-481
pubmed: 33479758
Clin Sci (Lond). 2020 Mar 13;134(5):543-545
pubmed: 32167153
Curr Pharm Des. 2015;21(35):5135-43
pubmed: 26350537
BMJ Open. 2021 Feb 16;11(2):e043625
pubmed: 33593784
Lancet Digit Health. 2021 Feb;3(2):e98-e114
pubmed: 33342753
Eur Heart J. 2020 May 14;41(19):1810-1817
pubmed: 32388565
Cardiovasc Drugs Ther. 2003 May;17(3):287-90
pubmed: 14669746
J Pharmacol Exp Ther. 1988 Oct;247(1):1-7
pubmed: 3171969
J Mol Cell Cardiol. 2014 Jan;66:167-76
pubmed: 24332999
Clin Sci (Lond). 2021 Jan 29;135(2):387-407
pubmed: 33511992
Clin Sci (Lond). 2020 Jun 26;134(12):1301-1304
pubmed: 32542396
N Engl J Med. 2020 Apr 23;382(17):1653-1659
pubmed: 32227760
Int J Mol Sci. 2020 Oct 28;21(21):
pubmed: 33126657
Gen Physiol Biophys. 2020 May;39(3):203-204
pubmed: 32525813
Viruses. 2021 Feb 16;13(2):
pubmed: 33669276
PLoS One. 2014 Oct 29;9(10):e110165
pubmed: 25353172
Eur Heart J. 2011 Nov;32(22):2739-47
pubmed: 21951628
J Travel Med. 2020 May 18;27(3):
pubmed: 32186711
Circ Res. 2020 May 8;126(10):1456-1474
pubmed: 32264791
Clin Diabetes Endocrinol. 2017 Jun 28;3:6
pubmed: 28702260
Antiviral Res. 2010 Mar;85(3):551-5
pubmed: 19995578
Clin Sci (Lond). 2020 Nov 27;134(22):2987-3006
pubmed: 33210709
Clin Sci (Lond). 2020 Dec 11;134(23):3229-3232
pubmed: 33305790
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14
pubmed: 18490652
Eur Heart J. 2020 May 14;41(19):1818-1820
pubmed: 32388547
Science. 1977 Apr 22;196(4288):441-4
pubmed: 191908
J Cardiovasc Pharmacol. 2020 Dec 04;77(3):323-331
pubmed: 33278189
Clin Sci (Lond). 2020 Apr 17;134(7):747-750
pubmed: 32255491
Physiol Res. 1999;48(1):1-8
pubmed: 10470860
Am J Physiol Lung Cell Mol Physiol. 2009 Jul;297(1):L84-96
pubmed: 19411314
Expert Rev Clin Pharmacol. 2020 Sep;13(9):921-924
pubmed: 32893686